Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 47


Comparative efficacy and safety of 4 randomized regimens to treat early Pseudomonas aeruginosa infection in children with cystic fibrosis.

Treggiari MM, Retsch-Bogart G, Mayer-Hamblett N, Khan U, Kulich M, Kronmal R, Williams J, Hiatt P, Gibson RL, Spencer T, Orenstein D, Chatfield BA, Froh DK, Burns JL, Rosenfeld M, Ramsey BW; Early Pseudomonas Infection Control (EPIC) Investigators.

Arch Pediatr Adolesc Med. 2011 Sep;165(9):847-56. doi: 10.1001/archpediatrics.2011.136.


Pseudomonas aeruginosa biofilms in cystic fibrosis.

Høiby N, Ciofu O, Bjarnsholt T.

Future Microbiol. 2010 Nov;5(11):1663-74. doi: 10.2217/fmb.10.125. Review.


Colistin-tobramycin combinations are superior to monotherapy concerning the killing of biofilm Pseudomonas aeruginosa.

Herrmann G, Yang L, Wu H, Song Z, Wang H, Høiby N, Ulrich M, Molin S, Riethmüller J, Döring G.

J Infect Dis. 2010 Nov 15;202(10):1585-92. doi: 10.1086/656788. Epub 2010 Oct 13.


Inhaled medication and inhalation devices for lung disease in patients with cystic fibrosis: poor adherence and the need to address it.

Duff AJ, Latchford GJ.

J Cyst Fibros. 2010 Dec;9(6):455-6. doi: 10.1016/j.jcf.2010.08.012. Epub 2010 Sep 16. No abstract available.


Controlled trial of cycled antibiotic prophylaxis to prevent initial Pseudomonas aeruginosa infection in children with cystic fibrosis.

Tramper-Stranders GA, Wolfs TF, van Haren Noman S, van Aalderen WM, Nagelkerke AF, Nuijsink M, Kimpen JL, van der Ent CK.

Thorax. 2010 Oct;65(10):915-20. doi: 10.1136/thx.2009.126128. Epub 2010 Aug 20.


An 18-month study of the safety and efficacy of repeated courses of inhaled aztreonam lysine in cystic fibrosis.

Oermann CM, Retsch-Bogart GZ, Quittner AL, Gibson RL, McCoy KS, Montgomery AB, Cooper PJ.

Pediatr Pulmonol. 2010 Nov;45(11):1121-34. doi: 10.1002/ppul.21301.


Effect of azithromycin on pulmonary function in patients with cystic fibrosis uninfected with Pseudomonas aeruginosa: a randomized controlled trial.

Saiman L, Anstead M, Mayer-Hamblett N, Lands LC, Kloster M, Hocevar-Trnka J, Goss CH, Rose LM, Burns JL, Marshall BC, Ratjen F; AZ0004 Azithromycin Study Group.

JAMA. 2010 May 5;303(17):1707-15. doi: 10.1001/jama.2010.563.


The role of azithromycin in patients with cystic fibrosis.

Yousef AA, Jaffe A.

Paediatr Respir Rev. 2010 Jun;11(2):108-14. doi: 10.1016/j.prrv.2009.12.003. Epub 2010 Jan 21. Review.


Garlic as an inhibitor of Pseudomonas aeruginosa quorum sensing in cystic fibrosis--a pilot randomized controlled trial.

Smyth AR, Cifelli PM, Ortori CA, Righetti K, Lewis S, Erskine P, Holland ED, Givskov M, Williams P, Cámara M, Barrett DA, Knox A.

Pediatr Pulmonol. 2010 Apr;45(4):356-62. doi: 10.1002/ppul.21193.


Antibiotic resistance of bacterial biofilms.

Høiby N, Bjarnsholt T, Givskov M, Molin S, Ciofu O.

Int J Antimicrob Agents. 2010 Apr;35(4):322-32. doi: 10.1016/j.ijantimicag.2009.12.011. Epub 2010 Feb 10. Review.


Inhaled versus systemic antibiotics and airway inflammation in children with cystic fibrosis and Pseudomonas.

Noah TL, Ivins SS, Abode KA, Stewart PW, Michelson PH, Harris WT, Henry MM, Leigh MW.

Pediatr Pulmonol. 2010 Mar;45(3):281-90. doi: 10.1002/ppul.21176.


Inflammation in Achromobacter xylosoxidans infected cystic fibrosis patients.

Hansen CR, Pressler T, Nielsen KG, Jensen PØ, Bjarnsholt T, Høiby N.

J Cyst Fibros. 2010 Jan;9(1):51-8. doi: 10.1016/j.jcf.2009.10.005. Epub 2009 Nov 25.


Polymorphonuclear leucocytes consume oxygen in sputum from chronic Pseudomonas aeruginosa pneumonia in cystic fibrosis.

Kolpen M, Hansen CR, Bjarnsholt T, Moser C, Christensen LD, van Gennip M, Ciofu O, Mandsberg L, Kharazmi A, Döring G, Givskov M, Høiby N, Jensen PØ.

Thorax. 2010 Jan;65(1):57-62. doi: 10.1136/thx.2009.114512. Epub 2009 Oct 21.


Extracellular DNA and F-actin as targets in antibiofilm cystic fibrosis therapy.

Tolker-Nielsen T, Høiby N.

Future Microbiol. 2009 Aug;4(6):645-7. doi: 10.2217/fmb.09.38. No abstract available.


Inhaled medication and inhalation devices for lung disease in patients with cystic fibrosis: A European consensus.

Heijerman H, Westerman E, Conway S, Touw D, Döring G; consensus working group.

J Cyst Fibros. 2009 Sep;8(5):295-315. doi: 10.1016/j.jcf.2009.04.005. Epub 2009 Jun 25. Review.


Early anti-pseudomonal acquisition in young patients with cystic fibrosis: rationale and design of the EPIC clinical trial and observational study'.

Treggiari MM, Rosenfeld M, Mayer-Hamblett N, Retsch-Bogart G, Gibson RL, Williams J, Emerson J, Kronmal RA, Ramsey BW; EPIC Study Group.

Contemp Clin Trials. 2009 May;30(3):256-68. doi: 10.1016/j.cct.2009.01.003. Epub 2009 Jan 15.


Efficacy and safety of inhaled aztreonam lysine for airway pseudomonas in cystic fibrosis.

Retsch-Bogart GZ, Quittner AL, Gibson RL, Oermann CM, McCoy KS, Montgomery AB, Cooper PJ.

Chest. 2009 May;135(5):1223-32. doi: 10.1378/chest.08-1421.


Pseudomonas aeruginosa biofilms in the respiratory tract of cystic fibrosis patients.

Bjarnsholt T, Jensen PØ, Fiandaca MJ, Pedersen J, Hansen CR, Andersen CB, Pressler T, Givskov M, Høiby N.

Pediatr Pulmonol. 2009 Jun;44(6):547-58. doi: 10.1002/ppul.21011.


Aerosol antibiotics in cystic fibrosis.

Geller DE.

Respir Care. 2009 May;54(5):658-70. Review.


Early aggressive eradication therapy for intermittent Pseudomonas aeruginosa airway colonization in cystic fibrosis patients: 15 years experience.

Hansen CR, Pressler T, Høiby N.

J Cyst Fibros. 2008 Nov;7(6):523-30. doi: 10.1016/j.jcf.2008.06.009. Epub 2008 Aug 9.

Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk